Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 11
2008 4
2009 1
2010 6
2011 3
2012 5
2013 7
2014 9
2015 5
2016 2
2017 4
2018 4
2019 1
2021 3
2022 1
2023 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
Roger SD, Wong CM, Vejakama P, Rahardjo KD, Hsu BG, Lee CM, Wu IW, Lee CC, Situmorang TD, Krisanapan P, Mazlan SA, Peng YS, Sarwono J, De Asis N, Solimen D, Jonny, Sangthawan P, Chen JB, Wang CL, Chung S, Villaflor AJ, Yang CW, Kan WC, Yang Y, Rubio-Bicol J, Yan LY, Lee SH, Chiu YW, Chen CH, Na KY, Hassah WHHW, Kang YS, Choi BS, Aquitania G, Na KR, Wu MS, Ahmad MK, Isidto R, Wu V, Leong GB, Sung JM, Noppakun K, Chou KJ, Abdul Wahab MZ, Shin SJ, Nugroho P. Roger SD, et al. Nephrology (Carlton). 2025 May;30(5):e70046. doi: 10.1111/nep.70046. Nephrology (Carlton). 2025. PMID: 40369895 Free PMC article. Clinical Trial.
CONCLUSION: Efepoetin alfa demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in correcting anaemia and maintaining haemoglobin (Hb) levels among stage 3 and 4 CKD patients. Moreover, the safety profile of efepoetin alfa wa …
CONCLUSION: Efepoetin alfa demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in co …
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Locatelli F, et al. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16. Clin J Am Soc Nephrol. 2019. PMID: 31420350 Free PMC article. Clinical Trial.
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of CKD. ...RESULT …
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoe …
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.
Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Fishbane S, et al. J Clin Pharmacol. 2007 Nov;47(11):1390-7. doi: 10.1177/0091270007307570. J Clin Pharmacol. 2007. PMID: 17962427 Clinical Trial.
C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, differs from traditional erythropoiesis-stimulating agents in its pharmacokinetic and receptor binding properties. . …
C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin recepto …
Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease.
Bartnicki P, Fijałkowski P, Majczyk M, Błaszczyk J, Banach M, Rysz J. Bartnicki P, et al. Med Sci Monit. 2013 Nov 8;19:954-9. doi: 10.12659/MSM.884024. Med Sci Monit. 2013. PMID: 24201565 Free PMC article. Clinical Trial.
The aim of the current study was to investigate the effect of a long half-life ESA, methoxy polyethylene glycol-epoetin beta (Mircera), on some markers of oxidative stress in predialysis patients with CKD. ...CONCLUSIONS: Our results suggest tha …
The aim of the current study was to investigate the effect of a long half-life ESA, methoxy polyethylene glycol-epoe …
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D; MAXIMA study investigators. Levin NW, et al. Lancet. 2007 Oct 20;370(9596):1415-21. doi: 10.1016/S0140-6736(07)61599-2. Lancet. 2007. PMID: 17950856 Clinical Trial.
We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. ...We did …
We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at …
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Klinger M, et al. Am J Kidney Dis. 2007 Dec;50(6):989-1000. doi: 10.1053/j.ajkd.2007.08.013. Am J Kidney Dis. 2007. PMID: 18037099 Clinical Trial.
BACKGROUND: C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals i …
BACKGROUND: C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin …
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.
Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC; PATRONUS Investigators. Carrera F, et al. Nephrol Dial Transplant. 2010 Dec;25(12):4009-17. doi: 10.1093/ndt/gfq305. Epub 2010 Jun 3. Nephrol Dial Transplant. 2010. PMID: 20522670 Free PMC article. Clinical Trial.
We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epoetin beta and darbepoetin alfa administered once monthly. ...Doses increased by 6.8% with methoxy …
We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene …
Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA, Meyer Reigner S, Tirodkar C, Drozdz D. Warady BA, et al. Am J Kidney Dis. 2023 Jun;81(6):684-694.e1. doi: 10.1053/j.ajkd.2022.11.006. Epub 2022 Dec 29. Am J Kidney Dis. 2023. PMID: 36587890 Clinical Trial.
RATIONALE & OBJECTIVE: The optimum starting dose of intravenous continuous erythropoietin receptor activator (C.E.R.A.) has been previously determined; this study ascertains the optimum starting dose of subcutaneous C.E.R.A. administration in pedia …
RATIONALE & OBJECTIVE: The optimum starting dose of intravenous continuous erythropoietin receptor activator …
Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F. Fischbach M, et al. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Clin J Am Soc Nephrol. 2018. PMID: 29097481 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator-methoxy polyethylene glycol- …
BACKGROUND AND OBJECTIVES: The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating ag …
Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.
Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S. Oh J, et al. J Korean Med Sci. 2014 Jan;29(1):76-83. doi: 10.3346/jkms.2014.29.1.76. Epub 2013 Dec 26. J Korean Med Sci. 2014. PMID: 24431909 Free PMC article. Clinical Trial.
Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a long-half life. ...
Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a long-half life. ...
63 results